Download Full Text (643 KB)

Document Type



The purpose of this literature review is to determine if there is a statistical difference in the safety and efficacy between romosozumab, the prototypical drug in the new drug class sclerostin inhibitors, versus alendronate, the prototypical bisphosphonate, in the treatment of postmenopausal osteoporosis. A comprehensive literature review was performed searching PubMed, EMBASE, and Access Medicine from the last five years. Works chosen for review were limited to articles published in English, full-text articles, clinical trials, randomized control trials, systematic reviews, and meta-analyses. Items were excluded after reviewing abstracts due to material not directly comparing the treatment modalities. The research presented shows beneficial evidence of bone formation and retention of bone density with treating postmenopausal women with osteoporosis with romosozumab for two years, followed by bisphosphonate therapy. However, the risks and benefits of this treatment regimen must be taken into consideration for each patient. Providers should take extra caution in starting romosozumab treatment in patients with cardiovascular health issues. Healthcare providers must take a thorough medical history and decide in collaboration with the patient about their treatment for osteoporosis. Current research on romosozumab does show promise in the treatment of osteoporosis. However, studies do show potential cardiovascular risk in starting romosozumab. Therefore, providers must take cation in starting this medication in patients with pervious cardiovascular co-morbidities

Date of Work


Publication Date



Romosozumab, alendronate, postmenopausal, female, human, efficacy


Medicine and Health Sciences

Comparing Romosozumab and Alendronate in the Treatment of Osteoporosis in Postmenopausal Women